Ralph E. Labaton

10 Years After Actavis, The Cases That Follow Tell A Story

D.C. Circuit Dismisses FTC Antitrust Suit: Exclusive Pharma Patent Licenses Remain Permissible Under The Patent Act

Xryem: Pharmaceutical Settlement Acceleration Clause Found Anticompetitive Due To Risk Of "Profit Crushing Competition"

FDA And FTC To Scrutinize Biologics Competition